Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Mattersburg – page 2

55 clinical trials in Mattersburg, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mattersburg at a glance
55
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

55 trials in Mattersburg

Open in trial search

Study of AP31969 compared to placebo to control heart rhythm in patients with atrial fibrillation

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:AP31969 sulfate
  • Sponsor:Acesion Pharma ApS

Osteoarthritis

Recruiting

Study on Treating Knee Osteoarthritis with Nasal Cartilage Implantation for Patients with Patellofemoral Osteoarthritis

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:N-Tec
  • Sponsor:Universitaetsspital Basel

Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study Comparing Rilvegostomig with Fluoropyrimidine and Trastuzumab Deruxtecan to Standard Treatment for Patients with HER2-positive Gastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astrazeneca AB

Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Astrazeneca AB

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Tendon injury+1

Recruiting

Study on Zoledronic Acid for Healing After Rotator Cuff Surgery in Patients with Tendon Rupture and Osteoporosis

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:AUVA Trauma Center Vienna

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Universitatsmedizin der Johannes Gutenberg-Universitat Mainz KöR

Study on Pancreatic Enzyme Replacement Therapy for Adults with Pancreatic Exocrine Insufficiency After Pancreatic Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pancreas Powder
  • Sponsor:MEDA Pharma GmbH & Co. KG

Study on the Effectiveness and Safety of Tinengotinib for Patients with Cholangiocarcinoma Resistant to Chemotherapy and FGFR Inhibitors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Transthera Sciences (Nanjing) Inc.

Study on TAK-330 for Reversing Anticoagulation in Patients on Factor Xa Inhibitors Needing Urgent Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Protein C
  • Sponsor:Takeda Development Center Americas Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Mattersburg

What the registry says about research in the country

01 Cardiovascular Diseases

In Mattersburg, clinical trial activity in cardiovascular diseases is focused on reducing the risk of serious heart complications and improving long-term outcomes for people with atherosclerotic cardiovascular disease.

  • Studies in atherosclerotic cardiovascular disease and broader cardiovascular disease
  • Research on preventing major heart events and related complications
  • Work aimed at improving treatment effectiveness for high-risk patients

These trials are helping assess whether new therapies can better protect patients from heart attacks, cardiovascular death, and other major events.

02 Nutritional and Metabolic Diseases

Clinical research in nutritional and metabolic diseases in this Austrian city is closely linked to obesity, overweight, and related metabolic risk factors that can affect heart and kidney health.

  • Trials involving obesity and overweight
  • Studies connecting weight-related conditions with cardiovascular disease
  • Research evaluating new approaches to improve metabolic health

The main goal is to understand whether emerging treatments can lower long-term disease burden and support better prevention.

03 Cardiovascular Risk Reduction

Several trials are examining whether investigational therapies can reduce the chance of first or repeat major cardiovascular events in participants with elevated risk factors.

  • Atherosclerotic Cardiovascular Disease and event prevention
  • Elevated Lp(a) as a key risk factor under study
  • Testing new options to reduce heart-related morbidity and mortality

This research focuses on whether better risk control can help prevent heart attacks, urgent procedures, and other serious outcomes.

04 Kidney and Cardiometabolic Health

Some studies also look beyond the heart, examining whether treatments can help preserve kidney function in people with overlapping cardiometabolic conditions.

  • Chronic Kidney Disease in combination with heart risk
  • People living with obesity and related complications
  • Trials exploring whether therapy can support both heart and kidney outcomes

These projects aim to find approaches that address multiple health concerns at once, which is especially important for patients with complex chronic disease.

05 Lipoprotein(a) Research

A notable area of investigation is Lipoprotein(a), or Lp(a), where researchers are testing whether lowering this inherited risk marker can reduce cardiovascular events.

  • Elevated Lp(a) and first major cardiovascular events
  • Studies focused on preventing coronary heart disease and myocardial infarction
  • Evaluating new strategies for people at heightened genetic risk

This work could improve prevention for patients whose heart risk remains high despite standard care.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.